Filtered By:
Drug: Eptifibatide

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 64 results found since Jan 2013.

Shear sensitive nanocapsule drug release for site specific inhibition of occlusive thrombus formation.
CONCLUSIONS: Targeted delivery of eptifibatide by shear-sensitive nanocapsules offers site specific antiplatelet potential and may form a basis for developing more potent and safer antiplatelet drugs. This article is protected by copyright. All rights reserved. PMID: 28267256 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 6, 2017 Category: Hematology Authors: Molloy CP, Yao Y, Kammoun H, Bonnard T, Hoefer T, Alt K, Tovar-Lopez F, Rosengarten G, Ramsland PA, van der Meer AD, van den Berg A, Murphy AJ, Hagemeyer CE, Peter K, Westein E Tags: J Thromb Haemost Source Type: research

Shear ‐sensitive nanocapsule drug release for site‐specific inhibition of occlusive thrombus formation
ConclusionsTargeted delivery of eptifibatide by shear‐sensitive nanocapsules offers site‐specific antiplatelet potential, and may form a basis for developing more potent and safer antiplatelet drugs.
Source: Journal of Thrombosis and Haemostasis - April 9, 2017 Category: Hematology Authors: C. P. Molloy, Y. Yao, H. Kammoun, T. Bonnard, T. Hoefer, K. Alt, F. Tovar ‐Lopez, G. Rosengarten, P. A. Ramsland, A. D. Meer, A. Berg, A. J. Murphy, C. E. Hagemeyer, K. Peter, E. Westein Tags: Original Article Source Type: research

Safety of Eptifibatide in Subarachnoid Hemorrhage Patients Requiring Antiplatelet Agents. (P2.285)
Conclusions:Our results indicate that administering IV Eptifibatide to prevent thrombotic complications after endovascular coil embolization in selected patients with aneurysmal subarachnoid hemorrhage is safe. Multicenter prospective trials are warranted to corroborate our findings.Disclosure: Dr. Mehta has nothing to disclose. Dr. Song has nothing to disclose. Dr. DeCarvalho has nothing to disclose. Dr. Z Arango has nothing to disclose. Dr. Kulhari has nothing to disclose. Dr. Kirmani has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Mehta, S., Song, Y.-B., DeCarvalho, B., Arango, A. Z., Kulhari, A., Kirmani, J. F. Tags: Subarachnoid Hemorrhage, Intracranial Aneurysm, and Other Cerebrovascular Malformations Source Type: research

UC lands largest grant ever for emergency medicine
The University of Cincinnati has been awarded a $29 million grant to study a clot-busting drug used to treat acute ischemic stroke, the largest amount ever awarded to the College of Medicine ’s Department of Emergency Medicine. The grant by the National Institutes of Health will fund research on the effectiveness of combining a drug known as tissue plasminogen activator, or tPA, with the blood thinners argatroban or eptifibatide. Plans call for 110 hospitals to take part in the stud y run through…
Source: bizjournals.com Health Care:Biotechnology headlines - June 1, 2018 Category: Biotechnology Authors: Barrett J. Brunsman Source Type: news

Potential applications of venom peptides as anti-thrombotic agents in arterial & deep-vein thrombosis.
CONCLUSION: Ancrod isolated from Malayan pit viper venom can cause reduction in level of blood fibrinogen and has been effectively tried in various ischemic conditions, including stroke. In order to search for novel lead molecules, the emphasis should be on isolation and characterization of pharmacologically active snake venoms proteins affecting blood coagulation and platelet aggregation. In this review an attempt has been made to recapitulates and discuss venoms of different animals and arthropod having anticoagulant peptides for their potential use in therapeutics and diagnostics. PMID: 29921198 [PubMed - as supplied by publisher]
Source: Protein and Peptide Letters - June 13, 2018 Category: Biochemistry Authors: Khan S, Gul A, Noreen R, Ashraf M, Ahmad S, Awan SB Tags: Protein Pept Lett Source Type: research

Use of Antiplatelet Agents in the Neurosurgical Patient
This article presents the relevant data supporting the use of antiplatelet agents in vascular neurosurgery and recommendations based on the described studies.
Source: Neurosurgery Clinics of North America - September 15, 2018 Category: Neurosurgery Authors: Amanda S. Zakeri, Shahid M. Nimjee Source Type: research

Routine Glycoprotein IIb/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-Analysis
ConclusionsRoutine GPI administration in STEMI resulted in mortality reduction, driven by reductions in recurrent ischemic events – however predominantly in trials pre-prasugrel/ticagrelor. Trials in contemporary STEMI management are needed to confirm these findings.
Source: Canadian Journal of Cardiology - May 8, 2019 Category: Cardiology Source Type: research

Routine Glycoprotein IIb/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-analysis
ConclusionsRoutine GPI administration in STEMI resulted in a reduction in mortality, driven by reductions in recurrent ischemic events—however predominantly in pre-prasugrel/ticagrelor trials. Trials with contemporary STEMI management are needed to confirm these findings.RésuméContexteLes lignes directrices recommandent le traitement d’appoint par des inhibiteurs des glycoprotéines IIb-IIIa (IGP) uniquement chez certains patients ayant subi un infarctus du myocarde avec élévation du segment ST (STEMI) aigu. Cette étude visait à évaluer l’utilisation systématique des IGP chez les patients ayant subi un STEMI ...
Source: Canadian Journal of Cardiology - November 2, 2019 Category: Cardiology Source Type: research

Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial.
CONCLUSIONS: In a contemporary NSTE ACS population, procedural complications with PCI remain frequent, are difficult to predict based on clinical characteristics, and are associated with worse ischaemic and haemorrhagic outcomes. PMID: 33518473 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - January 28, 2021 Category: Cardiology Authors: Abtan J, Wiviott SD, Sorbets E, Popovic B, Elbez Y, Mehta SR, Sabatine MS, Bode C, Pollack CV, Cohen M, Moccetti T, Laanmets P, Faxon D, Okreglicki A, Ducrocq G, Steg PG, TAO investigators Tags: Arch Cardiovasc Dis Source Type: research

Safety and Efficacy of Pharmaco-invasive Approach Using Streptokinase Compared With Primary Percutaneous Coronary Angiography
Conclusion: Utilizing streptokinase in early re-perfused patients by PI approach (≤3 hrs) seems safe and efficient when PPCI delay (>120 min from symptom onset) is the other option.
Source: Critical Pathways in Cardiology - August 28, 2021 Category: Cardiology Tags: Original Study Source Type: research

E-059 Eptifibatide bridging therapy for staged carotid artery stenting and cardiac surgery
ConclusionsFor patients undergoing staged CAS-CTS, Eptifibatide bridging therapy is a viable temporary antiplatelet strategy with a favorable safety profile. This strategy enables a flexible range of time-intervals between procedures.Disclosures M. Caton: None. K. Narsinh: None. A. Baker: None. J. Rapp: None. W. Gasper: None. J. Iannuzzi: None. E. Tseng: None. M. Amans: None. S. Hetts: None. D. Cooke: None.
Source: Journal of NeuroInterventional Surgery - July 26, 2021 Category: Neurosurgery Authors: Caton, M., Narsinh, K., Baker, A., Rapp, J., Gasper, W., Iannuzzi, J., Tseng, E., Amans, M., Hetts, S., Cooke, D. Tags: Electronic poster abstracts Source Type: research

Safety and Efficacy of Cangrelor Among Three Antiplatelet Regimens During Stent-Assisted Endovascular Treatment of Unruptured Intracranial Aneurysm: A Single-Center Retrospective Study
ConclusionThis single-center retrospective study compared 3 antiplatelet regimens, finding no significant difference in the safety and efficacy in the context of endovascular treatments of unruptured aneurysm using stent or flow diverters. This study adds data for the Cangrelor use and suggests its usefulness in the field of neuro-endovascular intervention. Randomized controlled studies are warranted to confirm these results.
Source: Frontiers in Neurology - March 4, 2022 Category: Neurology Source Type: research

Eptifibatide bridging therapy for staged carotid artery stenting and cardiac surgery: Safety and feasibility
CONCLUSIONS: For patients undergoing staged CAS-CTS, Eptifibatide bridging therapy is a viable temporary antiplatelet strategy with a favorable safety profile. This strategy enables a flexible range of time-intervals between procedures.PMID:35341420 | DOI:10.1177/17085381221084813
Source: Vascular - March 28, 2022 Category: Surgery Authors: M Travis Caton Kazim H Narsinh Amanda Baker Matthew R Amans Steven W Hetts Joseph H Rapp James C Ianuzzi Elaine Tseng Warren J Gasper Daniel L Cooke Source Type: research